CD3D & CD3E Heterodimer Antibody Guideline: Preparation, Dilution and Applications

CD3D & CD3E Heterodimer Antibody Overview

There are 6 CD3D & CD3E Heterodimer antibodies which are validated in multiple tissues with various applications, including ELISA, IHC-P, FCM. There are 2 CD3D & CD3E Heterodimer antibody for ELISA, 1 CD3D & CD3E Heterodimer antibody for IHC-P, 5 CD3D & CD3E Heterodimer antibody for FCM. Among all these CD3D & CD3E Heterodimer antibodies, there are 5 anti-CD3D & CD3E Heterodimer rabbit monoclonal antibodies , 1 anti-CD3D & CD3E Heterodimer rabbit polyclonal antibodies . All the CD3D & CD3E Heterodimer anbodies are produced in house and all are in stock. CD3D & CD3E Heterodimer antibody customerized service is available.

CD3D & CD3E Heterodimer Antibody ELISA

CD3D & CD3E Heterodimer antibody ELISA preparation

Produced in rabbits immunized with purified, recombinant Human CD3D & CD3E (rh CD3D & CD3E; Catalog#CT026-H0323H; P04234-1 & P07766-1; Met1-Ala105 & Met1-Asp126). Total IgG was purified by Protein A affinity chromatography.

CD3D & CD3E Heterodimer antibody ELISA validated

Application ELISA
Dilution 1:1000-1:2000
Notes  

CD3D & CD3E Heterodimer Antibody flow cytometry

CD3D & CD3E Heterodimer Antibody immunohistochemistry

CD3D & CD3E Heterodimer Antibody immunohistochemistry Preparation

This antibody was obtained from a rabbit immunized with purified, recombinant Human CD3D & CD3E Heterodimer (Catalog#CT026-H0323H; P04234-1 & P07766-1; Met1-Ala105 & Met1-Asp126).

CD3D & CD3E Heterodimer Antibody immunohistochemistry Validated

Application IHC
Dilution 1:100-1:500
Notes  

CD3D & CD3E Heterodimer antibody citations

Title
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
Year
2016
Author
Williams, GS;Mistry, B;Guillard, S;Ulrichsen, JC;Sandercock, AM;Wang, J;González-Muñoz, A;Parmentier, J;Black, C;Soden, J;Freeth, J;Jovanović, J;Leyland, R;Al-Lamki, RS;Leishman, AJ;Rust, SJ;Stewart, R;Jermutus, L;Bradley, JR;Bedian, V;Valge-Archer, V;Minter, R;Wilkinson, RW;
Journal
Oncotarget